Michael Rosenblum

Michael Rosenblum is Professor of Dermatology and Vice Chair of Research at the University of California San Francisco (UCSF) and is formally trained as an immunologist and a board-certified dermatologist. He graduated from UCSF’s prestigious Physician-Scientist Training Program in Dermatology and is the recipient of several distinguished awards, including the NIH’s New Innovator Award and a Burroughs Wellcome Career Development Award for Medical Scientists. The central focus of Dr. Rosenblum’s research is to understand the fundamental mechanisms of how immune responses are regulated and how this knowledge can be exploited for therapeutic benefit. Recent research has examined the biology of Regulatory T cells and Effector T cells resident within skin, humanized mouse models for studying the immunology of skin, and the interaction of the skin microbiome with the immune system. He was the scientific co-founder of Delinia Bio, which was acquired by Celgene. He is also co-founder of TRex Bio and Sitryx Bio, and has authored more than 85 basic science research papers. He received his M.D./Ph.D. from the Medical College of Wisconsin. He is a member of the American Association of Immunologists, Society for Investigative Dermatology, American Academy of Dermatology and Federation of Clinical Immunology Societies.